Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof
The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
1. A method of treating or ameliorating cancer in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of at least one compound selected from the group consisting of:
(i) a compound of Formula (I):
wherein in Formula (I):
R 1 is selected from the group consisting of C 1 -C 6 alkyl, haloalkyl, halo, nitro, —CN, C 1 -C 6 alkoxy, —C(═O)H, —C(═O)OH, —C(═O)—(C 1 -C 6 alkyl), and —SO 3 H; and,
each occurrence of R 2 is independently selected from the group consisting of H, C 1 -C 6 alkyl, haloalkyl, halo, nitro, —CN, C 1 -C 6 alkoxy, —C(═O)H, —C(═O)OH, —C(═O)—(C 1 -C 6 alkyl), and —SO 3 H; and,
(ii) a compound of Formula (II) where the naphthyl ring can be alpha or beta substituted:
wherein in Formula (II):
R 3 is selected from the group consisting of C 1 -C 6 alkyl, haloalkyl, halo, nitro, —CN, C 1 -C 6 alkoxy, —C(═O)H, —C(═O)OH, —C(═O)—(C 1 -C 6 alkyl), and —SO 3 H; and,
each occurrence of R 4 and R 5 is independently selected from the group consisting of H, C 1 -C 6 alkyl, haloalkyl, halo, nitro, —CN, C 1 -C 6 alkoxy, —C(═O)H, —C(═O)OH, —C(═O)—(C 1 -C 6 alkyl), and —SO 3 H;
mixtures thereof and salts thereof,
whereby said administering treats or ameliorates said cancer in said subject,
wherein said cancer has upregulated AKR1C3 expression and is selected from the group consisting of prostate cancer, breast cancer, endometrial cancer, acute myelogenous leukemia, and combinations thereof.
2. The method of claim 1 , wherein said prostate cancer comprises castrate resistant prostate cancer.
3. The method of claim 1 , wherein said cancer is androgen dependent.
4. The method of claim 1 , wherein said compound of Formula (I) is selected from the group consisting of 3-[N-(4-nitrophenyl)amino]benzoic acid, 3-[N-(4-acetylphenyl)amino]benzoic acid, 3-[N-(4-trifluoromethylphenyl)amino]benzoic acid, 3-[N-(4-chlorophenyl)amino]benzoic acid, 3-[N-(4-bromophenyl)amino]benzoic acid, 3-[N-(4-tert-butylphenyl)amino]benzoic acid, 3-[N-(4-methoxyphenyl)amino]-benzoic acid, 3-[N-(4-methylphenyl)amino]benzoic acid, mixtures thereof and salts thereof.
5. The method of claim 1 , wherein said compound of Formula (II) is 3-((4-nitronaphthalen-1-yl)amino)benzoic acid or a salt thereof.
6. The method of claim 1 , wherein said cancer is prostate cancer and wherein said method further comprises administering to said subject at least one therapeutic agent selected from the group consisting of indomethacin, desatinib, selegiline, seliciclib, TOK-001, SAHA, docetaxel, bevacizumab, taxotere, thalidomide, prednisone, Sipuleucel-T, cabazitaxel, MDV3100, ARN-509, abiraterone, temozolomide, mixtures thereof and salts thereof.
7. The method of claim 6 , wherein said composition and said at least one therapeutic agent are administered concomitantly to said subject.
8. The method of claim 7 , wherein said composition and said at least one therapeutic agent are co-formulated.
9. The method of claim 7 , wherein said cancer is breast cancer and wherein said method further comprises administering to said subject at least one therapeutic agent selected from the group consisting of tamoxifen, anastrozole, letrozole, vorozole, exemestane, fadrozole, formestane, raloxifene, mixtures thereof and salts thereof.
10. The method of claim 9 , wherein said composition and said at least one therapeutic agent are administered concomitantly to said subject.
11. The method of claim 10 , wherein said composition and said at least one therapeutic agent are co-formulated.
12. The method of claim 1 , wherein said subject is a human.